Related Experiment Videos
[Gemcitabine and breast cancer]
Benjamin Besse1, Jean-Philippe Spano
1Département de médecine, Institut Gustave-Roussy, 94805 Villejuif.
Bulletin Du Cancer
|November 27, 2002
Summary
Gemcitabine shows promise in metastatic breast cancer, especially in combination therapies for refractory cases. Further Phase III trials are ongoing to confirm its overall contribution to breast cancer treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Gemcitabine exhibits efficacy across various tumor types.
- Its favorable toxicity profile allows for combination therapies.
- Gemcitabine's role in metastatic breast cancer (MBC) is under investigation.
Purpose of the Study:
- To evaluate gemcitabine monotherapy and combination regimens in MBC.
- To identify effective gemcitabine combinations for refractory MBC patients.
- To assess the potential of gemcitabine-based treatments in different clinical settings.
Main Methods:
- Review of clinical evaluations of single-agent gemcitabine and gemcitabine-based combinations in MBC.
- Analysis of efficacy data, particularly in taxane and/or anthracycline refractory disease.
- Consideration of regimens used in neoadjuvant and first-line metastatic settings.
Main Results:
- Gemcitabine-vinorelbine combination shows high efficacy in refractory MBC.
- Gemcitabine-anthracycline-taxane regimens are effective in neoadjuvant and first-line MBC.
- Several gemcitabine combinations warrant further investigation.
Conclusions:
- Gemcitabine-based combinations demonstrate significant potential in MBC treatment.
- Specific combinations show promise for refractory disease and early-stage treatment.
- Results from ongoing Phase III trials are crucial for definitive conclusions on gemcitabine's contribution.